4-(5-甲基-1,2,4-恶二唑-3-基)苯甲醛 | 852180-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(5-甲基-1,2,4-恶二唑-3-基)苯甲醛
• 中文别名: 4-(5-甲基-1,2,4-恶二唑-3)-苯甲醛
• 英文名称: 4-(5-methyl-1,2,4-oxadiazol-3-yl)benzaldehyde
• CAS: 852180-60-0
• 化学式: C₁₀H₈N₂O₂
• mdl: MFCD07772818
• 分子量: 188.186
• InChiKey: BJICSBRPQDVEHP-UHFFFAOYSA-N

物化性质

• 熔点：
  115 °C
• 沸点：
  354.3±44.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-(5-甲基-1,2,4-恶二唑-3-基)苯甲醛 在 氯化亚砜 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 3-(4-(1-chloroethyl)phenyl)-5-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  WO2022/195022

  摘要：

  公开号：

文献信息

• Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary-Alcohol-Containing Transition-State Mimic
  作者：Xiongyu Wu、Per Öhrngren、Jenny K. Ekegren、Johan Unge、Torsten Unge、Hans Wallberg、Bertil Samuelsson、Anders Hallberg、Mats Larhed

  DOI：10.1021/jm070680h

  日期：2008.2.1

  A new generation of HIV-1 protease inhibitors encompassing a tertiary-alcohol-based transition-state mimic has been developed. By elongation of the core structure of recently reported inhibitors with two carbon atoms and by varying the P1' group of the compounds, efficient inhibitors were obtained with Ki down to 2.3 nM and EC50 down to 0.17 microM. Two inhibitor-enzyme X-ray structures are reported

  已经开发了包含基于叔醇的过渡态模拟物的新一代HIV-1蛋白酶抑制剂。通过延长最近报道的具有两个碳原子的抑制剂的核心结构，并通过改变化合物的P1'基团，可获得有效的抑制剂，其中Ki降至2.3 nM，EC50降至0.17 microM。报道了两种抑制剂-酶的X射线结构。
• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• Structure–Activity Relationship Studies of Pyrrolone Antimalarial Agents
  作者：Dinakaran Murugesan、Marcel Kaiser、Karen L. White、Suzanne Norval、Jennifer Riley、Paul G. Wyatt、Susan A. Charman、Kevin D. Read、Clive Yeates、Ian H. Gilbert

  DOI：10.1002/cmdc.201300177

  日期：2013.9

  Previously reported pyrrolones, such as TDR32570, exhibited potential as antimalarial agents; however, while these compounds have potent antimalarial activity, they suffer from poor aqueous solubility and metabolic instability. Here, further structure–activity relationship studies are described that aimed to solve the developability issues associated with this series of compounds. In particular, further

  先前报道的吡咯酮，如 TDR32570，显示出作为抗疟药的潜力；然而，虽然这些化合物具有有效的抗疟活性，但它们的水溶性较差且代谢不稳定。在这里，描述了进一步的构效关系研究，旨在解决与这一系列化合物相关的可开发性问题。特别是，对吡咯酮铅的进一步修饰，包括用哌啶取代苯环并通过支架啤酒花去除潜在代谢不稳定的酯，产生了对恶性疟原虫具有改善的体外抗疟活性的衍生物K1 是一种耐氯喹和乙胺嘧啶的寄生虫菌株，其某些衍生物对寄生虫的选择性优于哺乳动物 (L6) 细胞。选择了三种代表性化合物在疟疾感染的啮齿动物模型中进行评估，最好的化合物显示出减少寄生虫血症的能力有所提高，存活率略有增加。
• SUBSTITUTED PYRAZOLE COMPOUNDS
  申请人：Dyckman Alaric J.

  公开号：US20110275610A1

  公开（公告）日：2011-11-10

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R 1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, benzyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）化合物或其药学上可接受的盐，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环基，每个基团可选地被1至5个取自C1至C6烷基、C1至C4卤代烷基、苄基、—OR4和/或卤素的基团独立地取代；并且R2、R3、R4和n如本文所定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包括这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。
• SUBSTITUTED ISOXAZOLE COMPOUNDS
  申请人：Watterson Scott Hunter

  公开号：US20110300165A1

  公开（公告）日：2011-12-08

  Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R 1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）化合物或其药学上可接受的盐，其中Q是R1是烷基或芳基，所述芳基可选择性地被1到5个独立选择的取代基所取代，所述取代基选择自C1到C6烷基，C1到C4卤代烷基，-OR4和/或卤素; R2、R3、R4和n在此被定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中有用，例如自身免疫性疾病和血管疾病的治疗、预防或减缓疾病或障碍的进展。